Medical Condition News

RSS

High fructose diet can cause hypertension

People who eat a diet high in fructose, in the form of added sugar, are at increased risk of developing high blood pressure, or hypertension, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

2 Jul 2010

Research shows promising targeted therapies for type 2 diabetes patients

Named for the furballs whose astonishing fecundity made them stars in early Star Trek episodes, the tribbles protein, first identified in fruit flies, aids in regulating many cell processes in humans. Joslin Diabetes Center researchers now have identified mechanisms triggered by a variant of the tribbles gene that cause trouble in insulin-producing pancreatic beta cells—and that offer a promising target for therapies for people with type 2 diabetes, even if they don't carry that gene variant.

2 Jul 2010

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Now, in the first such study in living humans, researchers at UCLA suggest a cause, and it's not psychological, but physical: atrophy of a specific region of the hippocampus, a critical part of the brain involved in mood and memory, among other functions.

2 Jul 2010

Scientists explain mechanism behind acute myeloid leukemia

New research by scientists at Cold Spring Harbor Laboratory (CSHL) has illuminated in fine detail one of the genetic paths that leads to a particularly aggressive form of leukemia.

2 Jul 2010

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

United Therapeutics Corporation and Lee's Pharmaceutical Holdings Ltd. announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.

2 Jul 2010

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Older adults taking the antibiotic combination trimethoprim-sulfamethoxazole (TMP-SMX)—widely prescribed for urinary tract infections—are at increased risk of elevated potassium levels, called hyperkalemia, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

2 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

New asthma therapy shows promise for patients who do not respond to steroid treatments

A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Lupin's Famotidine for Oral Suspension receives FDA approval

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL). Commercial shipments of the product have already commenced.

2 Jul 2010

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

Wound Management Technologies, Inc. announced an important milestone in its planned growth strategy. Its wholly owned subsidiary Wound Care Innovations signed a distribution agreement with KOMED, LLC of Georgia for direct response advertising on television and niche online marketing of CellerateRx® in the United States.

1 Jul 2010

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

SAIC-Frederick, Inc. and Fluidigm Corporation are collaborating to decode the entire genome of the Epstein-Barr virus (EBV) using technology that can speed up research on the genetic basis of cancer and other diseases.

1 Jul 2010

Watson commences shipment of generic Exelon

Watson Pharmaceuticals, Inc. announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is used to treat dementia in people with Alzheimer's disease.

1 Jul 2010

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress.

1 Jul 2010

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

1 Jul 2010

Prasco to sell and distribute authorized generic version of ZEGERID capsules

Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured identically to the brand product and sold under a private label. Under the terms of a distribution and supply agreement with Santarus, Prasco will sell and distribute the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg and 40 mg strengths in the U.S. under the Prasco label.

1 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions

Studies of a more-rapid-acting injectable human insulin formulation (VIAject®) in the treatment of type 1 and type 2 diabetes and of a novel insulin analog formulation (Vialog™) in an animal model of diabetes were reported this week in three poster presentations at the 70th Scientific Sessions of the American Diabetes Association in Orlando, Florida. The findings are based upon results from recent clinical and preclinical studies sponsored by Biodel Inc..

1 Jul 2010

AAO-HNS releases CCS to address ambiguities, disparities in diagnosis and management of nasal valve compromise

Today, the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) announced the release of a consensus statement to address ambiguities and disparities in the diagnosis and management of nasal valve compromise (NVC).

1 Jul 2010

Research findings suggest new treatment approach to improve corneal transplants

Although it is already one of medicine's most successful transplant procedures, doctors continue to seek ways to improve corneal transplants. Now, for the first time, a team of German and British researchers have confirmed that failure and rejection of transplanted corneas are more likely in patients whose eyes exhibit abnormal vessel growth, called corneal neovascularization, prior to surgery.

1 Jul 2010

Medical Condition News

High fructose diet can cause hypertension

Research shows promising targeted therapies for type 2 diabetes patients

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Scientists explain mechanism behind acute myeloid leukemia

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Advanced Cancer Therapeutics secures $10M in investments

New asthma therapy shows promise for patients who do not respond to steroid treatments

Lupin's Famotidine for Oral Suspension receives FDA approval

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

Watson commences shipment of generic Exelon

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Prasco to sell and distribute authorized generic version of ZEGERID capsules

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions

AAO-HNS releases CCS to address ambiguities, disparities in diagnosis and management of nasal valve compromise

Research findings suggest new treatment approach to improve corneal transplants

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News